Biom Pharmaceutical Corporation
FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
May 08, 2024 09:25 ET | Biom Pharmaceutical Corporation
Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the...
VagiBiom® microbiome-based probiotic suppositories, the company’s flagship feminine care product.
Biom Pharmaceutical Published Clinical Safety & Efficacy of VagiBiom® Microbiome-based Probiotic Suppositories for Intimate Women's Health
February 27, 2024 08:35 ET | Biom Pharmaceutical Corporation
Sarasota, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Biom Pharmaceutical, a microbiome biotech company, announced today the publication of the results of the clinical study on VagiBiom®...